01
Med-Fine FamilyFinancing Progress
1. Orange Sail PharmaceuticalsAnnounced the completion of nearly 50 million US dollars in Pre-A round financingShanghai/Boston, December 31, 2024 — Oribio, a biopharmaceutical company focused on the discovery and development of multispecific antibodies and antibody-drug conjugates (ADCs), today announced the completion of a nearly US$50 million Pre-A round of financing. This round was led by Panacea Venture (Panacea Healthcare) and Shanghai Biomedical Fund, with continued support from existing shareholder HLC (Hillhouse Capital). Other well-known investment institutions, including Everjoy Fortune, Wanwu Venture Capital, Delian Capital, and Legend Star, also participated.This round of financing will be used to advance Orange Sails Pharma's innovative drug pipeline, accelerate core R&D projects into the clinical development stage, and focus on developing differentiated innovative therapeutic solutions for areas such as oncology and autoimmune diseases.Learn More
2. Saifu PharmaceuticalCompleted a strategic funding round led by Beijing Medical and Health Fund, ushering in a new chapter of development.Recently, SAFE Pharmaceutical Technology Co., Ltd. successfully completed a strategic funding round. This round was led by the Beijing Medical and Health Industry Investment Fund, with participation from several pharmaceutical industry investment institutions, marking a new chapter in Saifu Pharmaceutical's development. Previously, Saifu Pharmaceutical had completed multiple rounds of financing, gaining favor from well-known investment firms such as SDIC Venture Capital, China Life Equity Investment, Legend Capital, CICC Qide Fund under CICC Capital, Guoxin Fund, and Taiping Healthcare Fund.Learn More02
Med-Fine FamilyResearch Progress
1. China's First PARG InhibitorDanqing PharmaceuticalThe First Clinical Phase Trial Kick-off Meeting of DAT-2645 Tablets Successfully HeldOn December 19, 2024, the kick-off meeting for the Phase I clinical trial of DAT-2645, China's first domestically developed PARG inhibitor by Danqiao Pharmaceuticals, was successfully held at the Cancer Hospital of the Chinese Academy of Medical Sciences. The meeting was attended by experts and researchers from multiple departments in the oncology field, including Academician Binghe Xu (Leading PI), Associate Chief Physician Bo Lan (Sub-I), and Director Yu Tang of the GCP Center. Dr. Wenlai Zhou, Chairman and CEO of Danqiao Pharmaceuticals, along with the clinical medicine and R&D management teams, as well as SMO representatives, also participated in the event.Learn More
2. ArtivilaNovel Class 1 Drug ARD-885 Successfully Approved for Clinical Trials in China and the USRecently, the IND application for ARD-885, a novel Class 1 small molecule drug from Artivila's core pipeline for the treatment of rheumatoid arthritis (RA), has successfully received clinical trial approval from both the China National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). This marks the company’s official transition from the preclinical stage to the clinical stage.Learn More
3. MabworksKangyuan Bochuang Released Latest Clinical Trial Data of Trispecific Antibody MBS314 at the 2024 ASH Annual MeetingBeijing Mabworks Biotechnology Co., Ltd. and Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd. announced that the latest Phase I clinical trial data of their collaboratively developed trispecific antibody MBS314 will be presented at the 2024 American Society of Hematology (ASH) Annual Meeting, held in San Diego, USA, from December 7 to 10, 2024.Learn More
03
Med-Fine FamilyBusiness Breakthrough
1. ShanghaiEnsheng MedicalAwarded in the Fifth National Medical Consumables Group PurchasingShanghai Ensheng Medical Venous Stent System Ranks Fifth in the Fifth Batch of National Medical Consumables Procurement.Learn More
2. SanoMedAll-Series Ultrasonic Scalpel Wins Bid in Guangdong Alliance Centralized ProcurementSonoWe All 7 Models of Ultrasonic Scalpels Win Bids in Guangdong Alliance Centralized Procurement。Learn More
3. Zhongguancun Shuimu MedicalFirst Expansion into the Passive Field! Cybersecurity, Active Devices, and In Vitro Diagnostic Reagents Successfully Pass Reassessment and ExpansionOn December 12, Beijing Zhongguancun Shuimu Medical Technology Co., Ltd. successfully passed the expanded scope of testing capabilities, including fields such as passive medical devices, cybersecurity, active medical devices, and in vitro diagnostic reagents. Notably, this marks the first expansion for passive medical devices at Zhongguancun Shuimu Medical.Learn More
4. Zhongguancun Simo MedicalCNAS Expansion Review Approved, Qualification and Capability Upgraded AgainRecently, Zhongguan Village Shuimu Medical CNAS Reassessment, Relocation, and Expansion Application Successfully Approved! This expansion marks that Zhongguan Village Shuimu Medical has obtained the relevant IEC English standard qualifications, and its inspection and testing capabilities have been comprehensively confirmed and further expanded. The approval of the CNAS expansion fully demonstrates our relentless pursuit of continuous improvement and excellence, affirming our outstanding performance in technical capabilities, management levels, and service quality.Learn More
5. ByEpingThe provincial science and technology project "Guizhou Province Medical Device Safety Evaluation Base" responsible for construction has passed the acceptance inspection.Recently, the "Guizhou Provincial Medical Device Safety Evaluation Base" project built by EPIN (Guiyang) Quality Technology Co., Ltd. has successfully passed the acceptance of Guizhou Provincial Science and Technology Program, marking that EPIN's technical research and development and innovation capabilities have once again been officially recognized.Learn More
6. Chasing MedicineLabs in Two Locations Achieve Perfect Scores in PIK3CA and EML4-ALK Gene TestingRecently, the National Center for Clinical Laboratories (NCCL) under the National Health Commission of China announced the second round of External Quality Assessment (EQA) results for PIK3CA gene mutation testing and EML4-ALK fusion gene testing (PCR) in 2024. ChosenMed laboratories in Beijing and Hangzhou both achieved perfect scores of 100 points, with their accuracy and stability once again earning recognition from a national authoritative institution.Learn More
7. LiaoningGENECASTSuccessfully Passed CNAS Laboratory AccreditationIn December 2024, Liaoning Zhongke Gene Technology Co., Ltd. successfully passed the evaluation by the China National Accreditation Service for Conformity Assessment (CNAS) and was awarded the laboratory accreditation certificate, with the registration number CNAS L21991.Learn More
8. Heartview TechnologyThe First Batch to Settle in the "Digital Health Platform"In December 2024, Hangzhou Xinjing Technology was among the first batch of companies to join the "Digital Health New Quality Productivity Service Platform" (hereinafter referred to as the "Digital Health Platform"). This project aims to collaborate with regulatory agencies, research institutions, universities, medical institutions, and digital product and service supply-side enterprises in the field of digital health across China. Together, they will form a Digital Health New Quality Productivity Innovation Consortium. Centered around the 17 actions of Healthy China and the construction of Digital China, they will jointly build a Digital Health New Quality Productivity Service Platform to carry out supply-demand matchmaking, project cooperation, and compliant development, promote the application of scientific and technological achievements, facilitate concept validation, and better advance the construction of Digital China and Healthy China.Learn More
9. BeijingAnsong TechnologySuccessfully Approved as a Postdoctoral Research StationRecently, Beijing Ansom Tech Co., Ltd. successfully obtained approval from the Beijing Municipal Human Resources and Social Security Bureau for a postdoctoral research workstation within the industrial park. This officially grants the company the qualification to conduct postdoctoral training programs, marking a solid foundation for Ansom Tech in promoting technological innovation, building innovative research teams, and cultivating high-end talent.Learn More
04
Med-Fine FamilyBusiness Cooperation
1. AmepharmaComprehensive Strategic Cooperation Reached with Shanghai GaoBo Oncology Hospital Affiliated to China Pharmaceutical University for Global Innovative Drug IPG7236 Phase II Clinical Trial
Recently, I-Mab Biopharma announced a comprehensive strategic partnership with Shanghai GaoBo Oncology Hospital affiliated with China Pharmaceutical University regarding its self-developed IPG7236, the world’s first small-molecule antagonist targeting CCR8. According to the agreement, Shanghai GaoBo Oncology Hospital will continue to advance the Phase II clinical trial of IPG7236 based on the existing clinical trials, led by Professor Li Jin, Dean and Chief Scientist as well as Chief Physician of the hospital, who will serve as the Principal Investigator (PI) and take full responsibility for the Phase II clinical trial of IPG7236.Learn More
2. Saifu PharmaceuticalSign Strategic Cooperation with Huasai BermanOn December 24, 2024, Dr. Wang Quanjun, CEO and CSO of Saifu Pharmaceutical Group, was invited to engage in an exchange and signing ceremony with Huasai Borman. Gao Qing, Chairman of Huasai Borman, and relevant personnel attended the signing ceremony. With a solid foundation and high compatibility for cooperation, the two parties will further deepen collaboration in the development process of TIL cell drugs. Through strategic cooperation that leverages complementary strengths, they aim to expand areas of collaboration, jointly create a new situation of mutually beneficial development, and promote the development of TIL cell drugs.Learn More3. Saifu PharmaceuticalCollaborative Research Achievements in the CNS Field with Haisco Pharmaceutical Published in Journal
"Preclinical evaluation of abuse potential of the peripherally-restricted kappa opioid receptor agonist HSK21542"Learn More
4. Genetron HealthSuccessfully reached a cooperation agreement with EaseSalesRecently, Beijing Zhongke Gene Technology Co., Ltd. has reached a cooperation with SalesEase, the leader of CRM in China, and successfully held the CRM project launch conference. Zhongke Gene will leverage SalesEase's flexible PaaS platform capabilities to establish an integrated customer management platform system based on key scenarios such as LTC sales process management, data visualization analysis, and multi-department collaborative work. This will help the company more accurately target, connect with, and serve customers, achieving lean customer operations.Learn More
Med-Fine FamilyIndustry Honors
1. Dargo Biotech Wins JLABS Annual Innovation Best Deal Award at Johnson & Johnson Innovation JLABS Global CEO Summit2. Beijing Shuimu Jinsheng Medical Technology Service Co., Ltd. Awarded the Title of "Outstanding Cooperative Partner of the 2024 Promotion Plan"3. Shuimu Jingchuang Awarded "Outstanding Contribution Institution in the Robotics Industry Service"4. HeartPower Medical Included in the "List of Advanced Enterprises in Suzhou's Fourth Batch of Intellectual Property Strong Enterprise Cultivation Project"5. HeartPower Medical Selected for Two Lists: 2024 Emerging Medical Device Companies and High-Value Consumables Innovation6. Yipin Clinches Dual Honors: Guiyang Enterprise Technology Center and Suzhou Engineering Technology Research Center7. ZD Medical® Again Selected for "2024 Shanghai Intelligent Robot Benchmark Enterprises and Application Scenarios Recommended Directory"8. Two Founders of ZD Medical® Simultaneously Selected for Pudong New Area "Pearl Plan"9. Jiayan Medical Mitochondrial Hotspot Mutation Detection IVD Kit Honored on the Innovation Ranking List10. Jiayan Medical Ranks on "2024 Greater Bay Area Top 100 High-Growth Companies" List11. MicroMedicine Honored with Two Awards at the "Maker Beijing 2024" Innovation and Entrepreneurship Competition12. Microne Medicine Recognized as a Joint Talent Training Base in Beijing Economic-Technological Development Area13. MiFang Health Fund Ranks on "LP CLUB List · Top 20 Healthcare Investment Institutions of 2024" and Other Rankings
Med-Fine Award | Medfine Health Fund Ranks on Qimingpian"2024 China Equity Investment Annual List -- Top 15 in Healthcare"
